News
1d
TipRanks on MSNBioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer
The intervention being tested is BNT323/DB-1303, an investigational drug administered via intravenous infusion. It is compared against standard chemotherapy options, doxorubicin or paclitaxel, chosen ...
BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...
The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many ...
BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...
Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...
Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine ...
Yes, the Pfizer/BioNTech and Moderna Covid-19 vaccines have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA). Yes, that’s exciting news.
BioNTech , a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, saw its stock price decline by almost 34% over the last month, considerably underperforming the S&P 500 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results